Keyphrases
4E-BP1
21%
Actionable mutations
10%
Axillary Lymph Node Dissection
22%
Brain Tumor
9%
Breast Cancer
38%
Breast Cancer Patients
43%
Cell Signaling
15%
Chemotherapy
17%
Circulating Tumor DNA (ctDNA)
14%
Clinical Data
8%
Disease-free Survival
10%
Early Breast Cancer Patients
14%
Eukaryotic Translation Initiation Factor 4E (eIF4E)
23%
Genetic Heterogeneity
11%
Genetic Modification
13%
Glioblastoma
9%
HER2-positive
10%
HER2-positive Breast Cancer
17%
HER2-targeted Therapy
11%
Human Epidermal Growth Factor Receptor 2 (HER2)
44%
Human Epidermal Growth Factor Receptor 2-positive Breast Cancer
9%
Immunohistochemistry
8%
Intratumor Genetic Heterogeneity
8%
Ki-67
11%
Massively Parallel Sequencing
10%
Metastasis
10%
Molecular Assay
8%
Neoadjuvant Chemotherapy
13%
Neoadjuvant Therapy
29%
Nomogram
8%
Non-sentinel Lymph Node Metastasis
16%
One-step nucleic Acid Amplification
30%
P95HER2
13%
Patients with Breast Cancer
8%
Positive Sentinel Lymph Node
11%
Primary Breast Cancer
8%
Primary Tumor
14%
Protein Expression
8%
Residual Disease
9%
Sentinel Lymph Node
50%
Sentinel Lymph Node Biopsy
11%
Signaling Factors
8%
Terminal Fragment
8%
Therapeutic Target
9%
Total Tumor Load
21%
Trastuzumab
23%
Tumor
37%
Tumor Heterogeneity
14%
Tumor Protein p53 (TP53)
9%
Tumoral
14%
Medicine and Dentistry
Adjuvant Therapy
8%
Axillary Lymph Node
21%
Brain Metastasis
7%
BRCA1
10%
Breast Cancer
100%
Breast Tumor
8%
Cancer Stem Cell
7%
Cancer Therapy
8%
Cancer Types
7%
Carboxy Terminal Sequence
8%
Carcinoma
8%
Chemotherapy
9%
Circulating Tumor DNA
14%
Disease Free Survival
7%
Endometrium Carcinoma
7%
Epidermal Growth Factor Receptor
7%
Epidermal Growth Factor Receptor 2
23%
Estrogen Receptor
8%
Gamma Urogastrone
22%
Genetic Heterogeneity
19%
Glioblastoma
7%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
21%
Hypoxia
8%
Immunity
8%
Immunohistochemistry
9%
Initiation Factor 4E
16%
Initiation Factor 4E Binding Protein 1
7%
Intracranial Tumor
9%
Lymph Node Metastasis
7%
Malignant Neoplasm
24%
Metastatic Breast Cancer
7%
Metastatic Carcinoma
17%
Minimal Residual Disease
7%
Neoadjuvant Chemotherapy
13%
Neoadjuvant Therapy
23%
Neoplasm
81%
Nucleic Acid Amplification
24%
PARP Inhibitor
7%
Peroperative Echography
7%
Primary Tumor
17%
Prognostic Factor
9%
Proteomics
11%
Retroperitoneal Lymph Node Dissection
20%
Sentinel Lymph Node
35%
Sentinel Lymph Node Biopsy
10%
Sentinel Lymph Node Metastasis
10%
Signal Transduction
16%
Trastuzumab
13%
Triple Negative Breast Cancer
7%
Tumour Heterogeneity
14%